Evaluating the Safety and Efficacy of Autologous Adipose Tissue-derived Mesenchymal Stem Cell Transplantation on Proinflammatory Cytokines and Anti-inflammatory Cytokines on Ageing-related Low-grade Inflammation Patients.

Launched by DNA INTERNATIONAL HOSPITAL · Apr 23, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment approach using stem cells taken from a patient’s own fat tissue to see if it can help reduce inflammation related to aging. The focus is on patients who have low-grade inflammation, which can lead to various health issues as people age. The trial aims to determine if this treatment is safe and effective, particularly in patients who also have conditions like diabetes, high cholesterol, or obesity.

To participate, individuals must be between 40 and 64 years old and have higher than normal levels of certain inflammatory markers in their blood. They should also have at least two of the following conditions: type 2 diabetes, high cholesterol, or obesity. Participants can expect to undergo a series of evaluations and treatments as part of the study, but they will not be eligible if they have serious heart or breathing issues, cancer, or certain other health problems. This trial is currently recruiting participants, and everyone involved will work closely with the research team to ensure the safety and effectiveness of the treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male or female patient, age 40 to 64 years.
• • 2. The inflammatory aging patient as defined in the protocol as TNF alpha or IL6 at the time of screening was higher than the 95% healthy percentile value declared by the test system manufacturer.
• 3. Have at least 2 of the 3 following diseases:
• • Diabetes type II
• • Dyslipidemia
• • Obesity \[The diagnosis and determination of accompanying diseases (Diabetes, Dyslipidemia, Obesity) will be carried out according to the general guidance of the MOH Vietnam\].
• • 4. Patients are using stable drugs for co-infection (diabetes mellitus, dyslipidemia, obesity) stably in the past 3 months.
• • 5. Agree to participate in research and agree to comply with the research examination and evaluation process.
• Exclusion Criteria:
• • 1. Patients with a blood-clotting disorder or hemophilia
• • 2. Patients with severe heart failure
• • 3. Acute respiratory pathology at the time of screening
• • 4. Patients with cancer or other acute illness need treatment.
• • 5. Patients with a history of allergy to anesthetics, anesthesia, and antibiotics
• • 6. Patients are planning to participate in another clinical trial while participating in the study
• • 7. There are other conditions or circumstances in which it is difficult for researchers to ensure adherence to treatment in the judgment of researchers.